Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial.

Clin Transl Allergy · 2025 · PMC12628279 · PMID 41257453

Europe PMC DOI

hedged sentence

0.0556

closest p · 1.1× alpha

0.0556

boldest claim

The sentences

borderline significantp = 0.0556so close (0.05 < p ≤ 0.1)

A borderline significant interaction was observed for EASI‐90 response rate (37.1% vs. 18.8%, interaction p = 0.0556), indicating a trend toward more pronounced improvement in the comorbid subgroup.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.